Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma

European Journal of Radiology

Volumn 84, Issue 6, 2015, Pages 1023-1028

  Chakiba, Camille ^a   Cornelis, François ^b   Descat, Edouard ^c   Gross Goupil, Marine ^a   Sargos, Paul ^a   Roubaud, Guilhem ^a   Houédé, Nadine ^a,d  

^a INSTITUT BERGONIÉ   (France)

^b HÔPITAL PELLEGRIN   (France)

^c Saint Augustin Clinic   (France)

^d NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

Biomarker; Bladder carcinoma; Contrast; MRI; Neoadjuvant chemotherapy; Therapeutic response

Indexed keywords

CISPLATIN; GADOTERIC ACID; BIOLOGICAL MARKER; CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE; FEMALE; HUMAN; HUMAN TISSUE; IMAGING SYSTEM; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; ADJUVANT THERAPY; BLADDER TUMOR; DIAGNOSTIC USE; EVALUATION STUDY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, TRANSITIONAL CELL; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84929030983     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2015.02.026     Document Type: Article

References (36)

1. M. Ploeg, K.K. Aben, and L.A. Kiemeney The present and future burden of urinary bladder cancer in the world World J Urol 27 3 2009 289 293
2. J.P. Stein, and D.G. Skinner Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure World J Urol 24 3 2006 296 304
3. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Eur Urol 48 2 2005 202 205 discussion 5-6
4. G. Griffiths, R. Hall, R. Sylvester, D. Raghavan, and M.K. Parmar International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 16 2011 2171 2177
5. H.B. Grossman, R.B. Natale, C.M. Tangen, V.O. Speights, N.J. Vogelzang, and D.L. Trump Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 9 2003 859 866
6. H. Kitamura, T. Tsukamoto, T. Shibata, N. Masumori, H. Fujimoto, and Y. Hirao Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209 Ann Oncol 25 6 2014 1192 1198
7. F. Petrelli, A. Coinu, M. Cabiddu, M. Ghilardi, I. Vavassori, and S. Barni Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis Eur Urol 65 2 2014 350 357
8. R. Rosenblatt, A. Sherif, E. Rintala, R. Wahlqvist, A. Ullen, and S. Nilsson Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer Eur Urol 61 6 2012 1229 1238
9. G. Sonpavde, B.H. Goldman, V.O. Speights, S.P. Lerner, D.P. Wood, and N.J. Vogelzang Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy Cancer 115 18 2009 4104 4109
10. H.J. Lavery, K.D. Stensland, G. Niegisch, P. Albers, and M.J. Droller Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate J Urol 191 4 2014 898 906
11. A. Rajesh, H.K. Sokhi, R. Fung, K.A. Mulcahy, and M.J. Bankart Bladder cancer: evaluation of staging accuracy using dynamic MRI Clin Radiol 66 12 2011 1140 1145
12. A. Tekes, I. Kamel, K. Imam, G. Szarf, M. Schoenberg, and K. Nasir Dynamic MRI of bladder cancer: evaluation of staging accuracy AJR Am J Roentgenol 184 1 2005 121 127
13. M.J. Gollub, D.H. Gultekin, O. Akin, R.K. Do, J.L. Fuqua 3rd, and M. Gonen Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer Eur Radiol 22 4 2012 821 831
14. M.L. Marinovich, N. Houssami, P. Macaskill, G. von Minckwitz, J.U. Blohmer, and L. Irwig Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy J Natl Cancer Inst 105 5 2013 321 333
15. H.T. Nguyen, K.S. Pohar, G. Jia, Z.K. Shah, A. Mortazavi, and D.L. Zynger Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging Invest Radiol 49 6 2014 390 395
16. J.J. Shuster Median follow-up in clinical trials J Clin Oncol 9 1 1991 191 192
17. J.M. Bland, and D.G. Altman Multiple significance tests: the Bonferroni method BMJ 310 6973 1995 170
18. W.J. Youden Index for rating diagnostic tests Cancer 3 1 1950 32 35
19. R.J. de Haas, M.J. Steyvers, and J.J. Futterer Multiparametric MRI of the bladder: ready for clinical routine? AJR Am J Roentgenol 202 6 2014 1187 1195
20. B.P. Schrier, M. Peters, J.O. Barentsz, and J.A. Witjes Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer Eur Urol 49 4 2006 698 703
21. S. Yoshida, F. Koga, S. Kobayashi, H. Tanaka, S. Satoh, Y. Fujii, and K. Kihara Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer Int J Radiat Oncol Biol Phys 83 1 2012 11
22. K. Nishimura, C. Fujiyama, K. Nakashima, Y. Satoh, Y. Tokuda, and J. Uozumi The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall Int Urol Nephrol 41 4 2009 869 875
23. S.B. Donaldson, S.C. Bonington, L.E. Kershaw, R. Cowan, J. Lyons, and T. Elliott Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect Eur J Radiol 82 12 2013 2161 2168
24. J.A. Witjes, E. Comperat, N.C. Cowan, M. De Santis, G. Gakis, and T. Lebret EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines Eur Urol 65 4 2014 778 792
25. Q. Lin, Y. Liu, H. Chen, Q. Tang, and J. Liu Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer Mol Clin Oncol 1 5 2013 839 844
26. M. Cetin, E. Devrim, S. Serin Kilicoglu, I.B. Ergüder, M. Namuslu, and R. Cetin Ionic high-osmolar contrast medium causes oxidant stress in kidney tissue: partial protective role of ascorbic acid Ren Fail 30 5 2008 567 572
27. B. Barbaro, C. Fiorucci, C. Tebala, V. Valentini, M.A. Gambacorta, and F.M. Vecchio Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy Radiology 250 3 2009 730 739
28. U.B. Patel, F. Taylor, L. Blomqvist, C. George, H. Evans, and P. Tekkis Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience J Clin Oncol 29 28 2011 3753 3760
29. J. Bajpai, S. Gamnagatti, R. Kumar, V. Sreenivas, M.C. Sharma, and S.A. Khan Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis Pediatr Radiol 41 4 2011 441 450
30. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer Urology 83 2 2014 393 398
31. L.S. Mertens, A. Fioole-Bruining, E. Vegt, W.V. Vogel, B.W. van Rhijn, and S. Horenblas Impact of (18)F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle BJU Int 112 6 2013 729 734
32. H. von der Maase, S.W. Hansen, J.T. Roberts, L. Dogliotti, T. Oliver, and M.J. Moore Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 17 2000 3068 3077
33. A. Dash, J.A. Pettus 4th, H.W. Herr, B.H. Bochner, G. Dalbagni, and S.M. Donat A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience Cancer 113 9 2008 2471 2477
34. A.S. Fairey, S. Daneshmand, D. Quinn, T. Dorff, R. Dorin, and G. Lieskovsky Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California Urol Oncol 31 8 2013 1737 1743
35. A.B. Rosenkrantz, S. Kim, R.P. Lim, N. Hindman, F.M. Deng, and J.S. Babb Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales Radiology 269 2 2013 482 492
36. F. Cornelis, E. Tricaud, A.S. Lasserre, F. Petitpierre, J.C. Bernhard, and Y. Le Bras Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours Eur Radiol 24 5 2014 1068 1080